Similarly, in a small clinical trial in patients with basal cell carcinoma (NCT03714529), a PD-L1 peptide-based vaccination induced regression in tumors, even though PD-L1 was expressed only by immune cells in the TME and not by tumor cells [123]. Here, CD274 is linked to neoplasm.